CN108079089B - Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof Download PDFInfo
- Publication number
- CN108079089B CN108079089B CN201810062569.9A CN201810062569A CN108079089B CN 108079089 B CN108079089 B CN 108079089B CN 201810062569 A CN201810062569 A CN 201810062569A CN 108079089 B CN108079089 B CN 108079089B
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetic nephropathy
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 52
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 23
- 244000268590 Euryale ferox Species 0.000 claims abstract description 18
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 15
- 241001278833 Rosa laevigata Species 0.000 claims abstract description 14
- 235000000661 Rosa laevigata Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 5
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- 240000004980 Rheum officinale Species 0.000 claims abstract description 3
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims description 22
- 241001061264 Astragalus Species 0.000 claims description 20
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 19
- 210000004233 talus Anatomy 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 241000219061 Rheum Species 0.000 claims description 13
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 13
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 241000125175 Angelica Species 0.000 claims 3
- 241000218202 Coptis Species 0.000 claims 3
- 210000002700 urine Anatomy 0.000 abstract description 15
- 230000003907 kidney function Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000029142 excretion Effects 0.000 abstract description 3
- 229940126532 prescription medicine Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 244000247747 Coptis groenlandica Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 244000061520 Angelica archangelica Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 208000008967 Enuresis Diseases 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000021069 high fat-high sugar diet Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- -1 liquid paraffin Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating diabetic nephropathy, which comprises the following raw materials in parts by weight: 30-50 parts of astragalus membranaceus, 5-15 parts of angelica sinensis, 5-15 parts of gordon euryale seed, 5-20 parts of cherokee rose fruit, 30-50 parts of coptis chinensis and 5-15 parts of rheum officinale. The traditional Chinese medicine composition defines the medicinal components and the proportion of the effective prescription medicine for clinically treating the diabetic nephropathy, can obviously improve the early clinical symptoms of the diabetic nephropathy, obviously reduce the excretion of microalbumin in urine at the early stage of the diabetic nephropathy, protect the renal function and effectively prevent or delay the progress of the diabetic nephropathy.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof.
Background
Diabetic nephropathy is one of the most serious and common chronic complications of diabetic patients, and is also one of the main causes of end-stage nephropathy, and the incidence rate of the diabetic nephropathy is about 20-40%. Although the incidence of diabetic nephropathy is on the rise, no effective treatment means is available for diabetic nephropathy, and the application of chemosynthetic drugs is limited. The treatment principle is as follows: strictly controlling blood sugar, making the blood sugar close to normal level as far as possible, and preventing and delaying the occurrence of diabetic nephropathy; ② the rate of renal function decline is delayed; ③ dialysis treatment and kidney transplantation. Therefore, the traditional Chinese medicine has certain advantages in treating the diabetic nephropathy in an overall regulation way due to the nature, and becomes a common treatment method for the diabetic nephropathy.
The Chinese patent with the publication number of CN104971101A discloses a traditional Chinese medicine composition for treating diabetic nephropathy, which comprises the following raw material medicines in parts by weight: 10-120 parts of caulis sinomenii, 10-120 parts of flatstem milkvetch seed, 10-120 parts of astragalus root, 5-60 parts of coptis root and 5-50 parts of safflower.
The Chinese patent with the publication number of CN104758379A discloses a traditional Chinese medicine for treating diabetic nephropathy, which is prepared from the following raw medicinal materials in parts by weight: 6 parts of leech, 15 parts of salvia miltiorrhiza, 20 parts of ligusticum wallichii, 10 parts of red paeony root, 15 parts of cornus officinalis, 12 parts of achyranthes root, 15 parts of herba lycopi, 15 parts of semen lepidii and 15 parts of plantain seed.
The Chinese patent with the publication number of CN104888082A discloses a traditional Chinese medicine for treating diabetic nephropathy, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 8-16 parts of fructus psoraleae, 8-16 parts of fructus alpiniae oxyphyllae, 8-16 parts of semen cuscutae, 8-16 parts of radix achyranthis bidentatae, 8-16 parts of salvia miltiorrhiza, 8-16 parts of folium sennae, 4-8 parts of semen pharbitidis, 8-16 parts of angelica sinensis, 11-19 parts of prepared rehmannia root, 8-16 parts of donkey-hide gelatin, 8-16 parts of ginseng, 8-16 parts of rhizoma atractylodis macrocephalae, 8-16 parts of Chinese yam and 4-8 parts of liquorice.
Therefore, the utilization of traditional Chinese medicines for treating diabetic nephropathy becomes a hotspot of current research, and how to provide a traditional Chinese medicine composition with remarkable curative effect and small toxic and side effects has very important significance.
Disclosure of Invention
The invention aims to develop a traditional Chinese medicine composition for treating diabetic nephropathy, which defines the medicine compatibility and the dosage proportion of traditional Chinese medicines, can obviously improve the main clinical symptoms of the diabetic nephropathy, obviously reduce the excretion of microalbumin in urine of the diabetic nephropathy, regulate glycolipid metabolism, protect renal functions, effectively prevent or delay the progress of the diabetic nephropathy, does not find obvious adverse reactions, has good safety, and is an effective traditional Chinese medicine composition for treating the diabetic nephropathy.
The other purpose of the invention is to provide a preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy, which can effectively extract the main effective components contained in the traditional Chinese medicine composition.
In order to solve the technical problems, the invention provides the following technical scheme:
a traditional Chinese medicine composition for treating diabetic nephropathy comprises the following raw materials in parts by weight: 30-50 parts of astragalus membranaceus, 5-15 parts of angelica sinensis, 5-15 parts of gordon euryale seed, 5-20 parts of cherokee rose fruit, 30-50 parts of coptis chinensis and 5-15 parts of rheum officinale. Particularly, the characteristics of the traditional Chinese medicine composition are that the astragalus and the coptis are used in large dose, and the traditional Chinese medicine composition is very important for improving diabetic nephropathy indications.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 30 parts of astragalus, 10 parts of angelica, 10 parts of gordon euryale seed, 10 parts of cherokee rose fruit, 10 parts of coptis root and 6 parts of rhubarb.
Wherein the dosage form of the traditional Chinese medicine composition is tablets or capsules.
The preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy comprises the following steps:
(1) crushing the medicinal materials of gordon euryale seed and cherokee rose fruit, sieving the crushed medicinal materials with a No. 1 sieve, adding 5-10 times of water, soaking for 0.4-0.6 h, heating, decocting and extracting for 2 times, each time for 0.8-1.2 h, filtering, combining the filtrates, and concentrating under reduced pressure to obtain thick paste 1;
(2) crushing astragalus, angelica, coptis and rhubarb, sieving the crushed astragalus, angelica, coptis and rhubarb by a No. 1 sieve, adding 5-10 times of water, soaking for 0.4-0.6 h, heating, decocting and extracting for 2 times, each time for 0.8-1.2 h, filtering, combining filtrates, concentrating under reduced pressure, adding 95% ethanol until the alcohol concentration is 50-80%, uniformly mixing, standing, taking supernatant, and concentrating under reduced pressure to obtain thick paste 2;
(3) mixing the soft extracts 1 and 2, and mixing.
Preferably, in step (1), the density of the thick paste 1 measured at 60 ℃ is 1.10-1.15 g/ml.
In the step (2), the density of the thick paste 2 measured at 60 ℃ is 1.10-1.15 g/ml.
The efficacy of the various formulations adopted by the invention is as follows:
astragalus root: has effects of invigorating qi, consolidating superficial resistance, arresting sweating, promoting granulation, inducing diuresis, and relieving swelling. Can be used for treating deficiency of vital energy, asthenia, collapse of middle-warmer energy, chronic diarrhea, proctoptosis, hematochezia, metrorrhagia, superficial deficiency, spontaneous perspiration, carbuncle, cellulitis, intractable ulcer, blood deficiency, sallow complexion, internal heat, diabetes, chronic nephritis, albuminuria, diabetes, etc. Huang Qi Zhi has the actions of tonifying qi and strengthening middle energizer, while the raw one is used for strengthening exterior and relieving sore.
Chinese angelica: sweet, pungent, bitter and warm in nature; it enters liver, heart and spleen meridians; used for various syndromes of blood deficiency; menoxenia; amenorrhea; dysmenorrhea; the accumulation of symptoms; (ii) metrorrhagia and metrostaxis; abdominal pain due to deficiency-cold; flaccidity and paralysis; numbness of the skin; intestinal dryness and difficult defecation; severe dysentery with diarrhea; carbuncle, cellulitis, sore and ulcer; injury from falling.
Gorgon fruit: the astringent in the gorgon fruit traditional Chinese medicine has the functions of tonifying middle-jiao and Qi, tonifying kidney and securing essence, and removing dampness and stopping leukorrhagia; can be used for treating nocturnal emission, enuresis, frequent micturition, spleen deficiency, chronic diarrhea, whitish and turbid urine, and leukorrhagia.
Cherokee rose fruit: sour, sweet, astringent and neutral. It enters kidney, bladder and large intestine meridians. Can secure essence and reduce urination, astringe intestines and stop diarrhea, the cherokee rose contains a great amount of acid substances, soap and the like, can secure essence and prevent spermatorrhea and diarrhea of men and leukorrhagia of women, can also secure intestinal tracts and prevent diarrhea and dysentery caused by spleen deficiency and poor restraint. Can also be used for arresting urination and enuresis, contains a large amount of acidic substances and saponins, has effects of restricting upper sphincter from dropping, prolonging urination time interval, and increasing urine output per time, and can be used for treating enuresis and frequent micturition.
Coptis chinensis: the product is dried rhizome of Coptidis rhizoma of Ranunculaceae; bitter taste and cold nature; the channels of heart, spleen, stomach, liver, gallbladder and large intestine; clear heat and dry dampness, purge fire and remove toxicity.
Rhubarb: nature and taste: bitter and cold. Meridian tropism: stomach, large intestine, liver and spleen meridians; clearing away damp-heat: it can conduct damp-heat out of the stool. The main treatment is as follows: constipation due to excess heat; heat retention in the chest and fullness; dysentery due to damp-heat; jaundice; gonorrhea; edema and abdominal fullness; difficulty in urination; conjunctival congestion; swollen and sore throat; sores develop in the mouth and tongue.
The formula is reasonable in compatibility, and the medicines are combined to play the effects of tonifying kidney and qi, removing blood stasis and dredging collaterals, expelling toxin and discharging turbidity, and enriching blood and nourishing blood, so that the pathogenesis of early diabetic nephropathy is fastened, and the renal function of a patient can be obviously improved.
The invention has the beneficial effects that:
(1) the traditional Chinese medicine composition defines the medicinal components and the proportion of an effective prescription for clinically treating diabetic nephropathy, can obviously improve the early clinical symptoms of the diabetic nephropathy, obviously reduce the excretion of microalbumin in urine at the early stage of the diabetic nephropathy, regulate the glycometabolism, protect the renal function and effectively prevent or delay the progress of the diabetic nephropathy; (2) the composition is a traditional Chinese medicine formula, has no obvious adverse reaction and has good safety; the traditional Chinese medicine composition has comprehensive effects and better medicine treatment effect, obviously improves the medication compliance of the diabetic patients, and improves the life quality of the patients; (3) the components of the traditional Chinese medicine composition are extracted from conventional natural traditional Chinese medicinal materials, and the raw materials are convenient and easy to obtain; the extraction process is simple and easy to operate, the process index is easy to control, and the whole process is easy to realize industrial production; (4) the Chinese medicinal composition has flexible and various preparation types, can be prepared into dosage forms such as tablets, capsules and the like which are convenient to take orally according to different requirements, is convenient to use, is suitable for long-term administration treatment of diabetic nephropathy, and is easily accepted by patients; it also has the advantages of good therapeutic effect, low cost, high therapeutic effect, etc.
Drawings
FIG. 1 is a graph showing the body weight changes of rats in different treatment groups according to example 1 of the present invention;
FIG. 2 is the body weight of rats of different treatment groups at the end of the experiment in example 1 of the present invention;
FIG. 3 is a graph showing the blood glucose changes of rats in different treatment groups according to example 1 of the present invention;
FIG. 4 is the blood glucose of rats of different treatment groups at the end of the experiment in example 1 of the present invention;
FIG. 5 shows the change in microalbumin in 24h urine in rats from different treatment groups according to example 1 of the present invention;
FIG. 6 shows 24h urine microalbumin at the end of the experiment in example 1 of the present invention in rats from different treatment groups;
FIG. 7 shows the body weight changes of rats in different treatment groups according to example 3 of the present invention;
FIG. 8 is the body weight of rats of different treatment groups at the end of the experiment in example 3 of the present invention;
FIG. 9 shows the blood glucose changes of rats in different treatment groups according to example 3 of the present invention;
FIG. 10 is the blood glucose of rats of different treatment groups at the end of the experiment in example 3 of the present invention;
FIG. 11 shows the 24h urine microalbumin changes in rats from different treatment groups according to example 3 of the present invention;
FIG. 12 is 24h urine microalbumin from different treatment groups of rats at the end of the experiment in example 3 of the invention.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1
A traditional Chinese medicine composition for treating diabetic nephropathy comprises the following raw materials in parts by weight: 30 parts of astragalus, 5 parts of angelica, 5 parts of gordon euryale seed, 5 parts of cherokee rose fruit, 30 parts of coptis root and 5 parts of rhubarb.
The preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy comprises the following steps:
(1) pulverizing semen euryales and fructus Rosae Laevigatae, sieving with No. 1 sieve (10 mesh), soaking in 5 times of water for 0.4 hr, heating, decocting for 2 times (each time for 1.2 hr), filtering, mixing filtrates, and concentrating under reduced pressure to obtain soft extract (density of 1.12g/ml at 60 deg.C) to obtain soft extract 1;
(2) pulverizing radix astragali, radix Angelicae sinensis, Coptidis rhizoma, and radix et rhizoma Rhei, sieving with No. 1 sieve, adding 5 times of water, soaking for 0.4h, heating, decocting for 2 times, each for 1.2h, filtering, mixing filtrates, concentrating under reduced pressure (density 1.06g/ml measured at 60 deg.C), adding 95% ethanol until alcohol concentration reaches 60%, mixing, standing for 12h, collecting supernatant, and concentrating under reduced pressure to obtain soft extract (density 1.13g/ml measured at 60 deg.C) to obtain soft extract 2;
(3) mixing the soft extracts 1 and 2, mixing, adding pharmaceutical adjuvants such as microcrystalline cellulose, starch, magnesium stearate, etc., tabletting, and making into tablet.
Compared with the traditional Chinese medicine composition which uses astragalus and coptis in large dose, the traditional proportioning group of the astragalus and the coptis is selected as a reference, namely 10 parts of the astragalus, 5 parts of angelica, 5 parts of gordon euryale seed, 5 parts of cherokee rose fruit, 10 parts of coptis and 5 parts of rhubarb. The same preparation formulation is prepared according to the same preparation process.
Experimental animals: healthy male Wistar rats, 5 weeks old, 70, 150-170 g, purchased from Beijing Wittingle laboratory animal technology Limited, were raised in a clean animal room of animal building, Beijing century Tan Hospital, affiliated to the university of capital medicine, at a temperature of 20-25 ℃, with a relative humidity of 55 + -15%, with proper ventilation and reasonable illumination.
Preparation and experimental grouping of animal models: after the rats are purchased, the rats are adaptively fed for 1 week, the blood sugar and the body weight of the rats in the basic state are measured, all the rats are divided into a normal control group, a model group, a positive drug group (fosinopril) (1.05mg/kg), a tablet high dose group (15.96g/kg), a tablet medium dose group (7.98g/kg) and a tablet low dose group (3.99g/kg) according to the body weight by adopting a random grouping design, the conventional proportioning group (15.96g/kg) keeps the same administration dose with the tablet high dose group, and 10 rats are respectively arranged in each group. The normal group rats were given maintenance diet throughout the entire experimental period, while the model group rats were given high-fat high-sugar diet at the formal start of the experiment. After 8 weeks, rats in the normal group were intraperitoneally injected with 0.1mmoL/L citric acid-sodium citrate buffer at a dose of 3 mL/kg; the model group is injected with 1% streptozotocin solution in the abdominal cavity at the dose of 30mg/kg, blood is collected from the tail tip after 72 hours to detect the blood sugar, and the blood sugar value is higher than 16.7mmoL/L to be used as the successful standard of the diabetes model. Administration was started 4 weeks after STZ injection and 12 weeks.
Evaluation indexes are as follows: blood glucose, body weight and 24h urine microalbumin were measured every 4 weeks during the dosing period.
As a result: the combined drug tablet has a better protective effect on diabetic nephropathy rats, the weight of diabetic nephropathy animals is increased to different degrees by the administration doses of the positive drug and the tablet (compared with a model group, P is less than 0.05), and the conventional proportioning group does not show the trend of significant weight increase (compared with the model group, P is more than 0.05); the medium and high dose groups of the tablets show obvious effect of reducing the blood sugar of diabetic nephropathy rats (P <0.05 compared with the model group), while the conventional proportioning group does not show obvious effect of reducing the blood sugar (P >0.05 compared with the model group); each tablet administration dose group can obviously reduce 24h urine microalbumin (P <0.05 compared with a model group), while the conventional proportioning group does not show obvious reduction of 24h urine microalbumin (P >0.05 compared with the model group), and the results are shown in figures 1-6.
Example 2
A traditional Chinese medicine composition for treating diabetic nephropathy comprises the following raw materials in parts by weight: 40 parts of astragalus, 8 parts of angelica, 8 parts of gordon euryale seed, 8 parts of cherokee rose fruit, 40 parts of coptis root and 8 parts of rhubarb.
The preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy comprises the following steps:
(1) pulverizing semen euryales and fructus Rosae Laevigatae, sieving with No. 1 sieve, soaking in 8 times of water for 0.5 hr, heating, decocting for 2 times, each for 1 hr, filtering, mixing filtrates, and concentrating under reduced pressure to obtain soft extract (density of 1.10g/ml at 60 deg.C) to obtain soft extract 1;
(2) pulverizing radix astragali, radix Angelicae sinensis, Coptidis rhizoma, and radix et rhizoma Rhei, sieving with No. 1 sieve, adding 8 times of water, soaking for 0.5h, heating, decocting for 2 times, each time for 1h, filtering, mixing filtrates, concentrating under reduced pressure (density of 1.07g/ml at 60 deg.C), adding 95% ethanol to alcohol concentration of 70%, mixing, standing for 12h, collecting supernatant, and concentrating under reduced pressure to obtain soft extract (density of 1.15g/ml at 60 deg.C) to obtain soft extract 2;
(3) mixing the soft extracts 1 and 2, mixing, adding medicinal adjuvants such as dextrin, calcium hydrogen phosphate, liquid paraffin, and sodium carboxymethyl starch, and making capsule No. 1.
Compared with the traditional Chinese medicine composition which uses astragalus and coptis in large dose, the traditional proportioning group of astragalus and coptis is selected as a reference, namely 8 parts of astragalus, 8 parts of angelica, 8 parts of gordon euryale seed, 8 parts of cherokee rose fruit, 8 parts of coptis and 8 parts of rhubarb. The same preparation formulation is prepared according to the same preparation process.
Example 3
A traditional Chinese medicine composition for treating diabetic nephropathy comprises the following raw materials in parts by weight: 50 parts of astragalus, 15 parts of angelica, 15 parts of gordon euryale seed, 20 parts of cherokee rose fruit, 50 parts of coptis root and 15 parts of rhubarb.
The preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy comprises the following steps:
(1) pulverizing semen euryales and fructus Rosae Laevigatae, sieving with No. 1 sieve, soaking in 10 times of water for 0.6 hr, heating, decocting for 2 times (each time for 0.8 hr), filtering, mixing filtrates, and concentrating under reduced pressure to obtain soft extract (density of 1.15g/ml at 60 deg.C) to obtain soft extract 1;
(2) pulverizing radix astragali, radix Angelicae sinensis, Coptidis rhizoma, and radix et rhizoma Rhei, sieving with No. 1 sieve, adding 10 times of water, soaking for 0.6h, heating, decocting for 2 times, each time for 0.8h, filtering, mixing filtrates, concentrating under reduced pressure (density of 1.07g/ml at 60 deg.C), adding 95% ethanol to alcohol concentration of 70%, mixing, standing for 12h, collecting supernatant, and concentrating under reduced pressure to obtain soft extract (density of 1.10g/ml at 60 deg.C) to obtain soft extract 2;
(3) mixing the soft extracts 1 and 2, mixing, adding medicinal adjuvants such as dextrin, calcium hydrogen phosphate, liquid paraffin, and sodium carboxymethyl starch, and making capsule No. 1.
Compared with the traditional Chinese medicine composition which uses astragalus and coptis root in large dose, the traditional proportioning group of the astragalus and the coptis root is selected as a reference, namely 12 parts of the astragalus, 15 parts of angelica, 15 parts of gordon euryale seed, 20 parts of cherokee rose fruit, 6 parts of coptis root and 15 parts of rhubarb. The same preparation formulation is prepared according to the same preparation process.
Experimental animals: healthy male Wistar rats, 5 weeks old, 70 rats, 160-180 g, purchased from Beijing Wittingle laboratory animal technology Limited, were raised in a clean animal room of animal building, Beijing century Tan Hospital, affiliated to the university of capital medicine, at a temperature of 20-25 ℃, with a relative humidity of 55 + -15%, with proper ventilation and reasonable illumination.
Preparation and experimental grouping of animal models: after the rats are purchased, the rats are adaptively fed for 1 week, the blood sugar and the body weight of the rats in the basic state are measured, all the rats are divided into a normal control group, a model group, a positive drug group (fosinopril) (1.03mg/kg), a capsule high dose group (16.06g/kg), a capsule medium dose group (8.08g/kg) and a capsule low dose group (4.04g/kg) according to the body weight by adopting a random grouping design, the conventional proportioning group (16.06g/kg) keeps the same administration dose with the capsule high dose group), and 10 rats are respectively arranged in each group. The normal group rats were given maintenance diet throughout the entire experimental period, while the model group rats were given high-fat high-sugar diet at the formal start of the experiment. After 8 weeks, rats in the normal group were intraperitoneally injected with 0.1mmoL/L citric acid-sodium citrate buffer at a dose of 3 mL/kg; the model group is injected with 1% streptozotocin solution in the abdominal cavity at the dose of 30mg/kg, blood is collected from the tail tip after 72 hours to detect the blood sugar, and the blood sugar value is higher than 16.7mmoL/L to be used as the successful standard of the diabetes model. Administration was started 4 weeks after STZ injection and 12 weeks.
Evaluation indexes are as follows: blood glucose, body weight and 24h urine microalbumin were measured every 4 weeks during the dosing period; at the end of the experiment the animals were sacrificed under chloral hydrate anaesthesia, blood was taken from the abdominal aorta, serum was centrifuged and tested for total serum protein (TP), Albumin (ALB), Blood Urea Nitrogen (BUN), creatinine (Scr).
As a result: the combined medicine capsule has a good protective effect on diabetic nephropathy rats, the weight of diabetic nephropathy animals is increased to different degrees by the administration doses of the positive medicine and the capsule (compared with a model group, P is less than 0.05), and the conventional proportioning group does not show the trend of significant weight increase (compared with the model group, P is more than 0.05); the middle and high dose groups of the capsule show obvious effect of reducing the blood sugar of diabetic nephropathy rats (compared with the model group P <0.05), while the conventional proportioning group does not show obvious effect of reducing the blood sugar (compared with the model group P > 0.05); each administration dose group of the capsule can obviously reduce 24h urine microalbumin (P is less than 0.05 compared with a model group), while the conventional proportioning group does not show obvious reduction of 24h urine microalbumin (P is more than 0.05 compared with the model group), and the results are shown in figures 7-12.
The technical solutions described above only represent the preferred technical solutions of the present invention, and some possible modifications to some parts of the technical solutions by those skilled in the art all represent the principles of the present invention, and fall within the protection scope of the present invention.
Claims (6)
1. The traditional Chinese medicine composition for treating diabetic nephropathy is characterized by comprising the following raw materials in parts by weight: 30-50 parts of astragalus membranaceus, 5-15 parts of angelica sinensis, 5-15 parts of gordon euryale seed, 5-20 parts of cherokee rose fruit, 30-50 parts of coptis chinensis and 5-15 parts of rheum officinale.
2. The traditional Chinese medicine composition for treating diabetic nephropathy according to claim 1, which is prepared from the following raw materials in parts by weight: 40 parts of astragalus, 8 parts of angelica, 8 parts of gordon euryale seed, 8 parts of cherokee rose fruit, 40 parts of coptis root and 8 parts of rhubarb.
3. The traditional Chinese medicine composition for treating diabetic nephropathy according to claim 1 or 2, wherein the dosage form of the traditional Chinese medicine composition is tablet or capsule.
4. A method of preparing the traditional Chinese medicine composition for treating diabetic nephropathy of claim 1, the method comprising the steps of:
(1) pulverizing semen euryales and fructus Rosae Laevigatae, sieving with a No. 1 sieve, adding 5-10 times of water, soaking for 0.4-0.6 h, heating, decocting and extracting for 2 times, each time for 0.8-1.2 h, filtering, mixing filtrates, and concentrating under reduced pressure to obtain soft extract 1;
(2) crushing astragalus, angelica, coptis and rhubarb, sieving the crushed astragalus, angelica, coptis and rhubarb by a No. 1 sieve, adding 5-10 times of water, soaking for 0.4-0.6 h, heating, decocting and extracting for 2 times, each time for 0.8-1.2 h, filtering, combining filtrates, concentrating under reduced pressure, adding 95% ethanol until the alcohol concentration is 50-80%, uniformly mixing, standing, taking supernatant, and concentrating under reduced pressure to obtain thick paste 2;
(3) mixing the soft extracts 1 and 2, and mixing.
5. The preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy according to claim 4, wherein in the step (1), the density of the thick paste 1 measured at 60 ℃ is 1.10-1.15 g/ml.
6. The preparation method of the traditional Chinese medicine composition for treating diabetic nephropathy according to claim 4, wherein in the step (2), the density of the thick paste 2 measured at 60 ℃ is 1.10-1.15 g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810062569.9A CN108079089B (en) | 2018-01-23 | 2018-01-23 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810062569.9A CN108079089B (en) | 2018-01-23 | 2018-01-23 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108079089A CN108079089A (en) | 2018-05-29 |
| CN108079089B true CN108079089B (en) | 2020-12-22 |
Family
ID=62182496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810062569.9A Active CN108079089B (en) | 2018-01-23 | 2018-01-23 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108079089B (en) |
-
2018
- 2018-01-23 CN CN201810062569.9A patent/CN108079089B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 固肾解毒法治疗糖尿病肾病早期的临床观察;冯兴中等;《北京中医药大学学报》;20110430;第34卷(第4期);第286-288页，尤其是第286页1.2一般资料、2.1治疗方法和第287页3.4疗效评定结果 * |
| 大剂量黄连对糖尿病肾病大鼠糖化血红蛋白、TNF-α及肾脏病理的影响;郭杨志等;《时珍国医国药》;20171231;第28卷(第4期);第830-832页，尤其是第830页摘要和第831页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108079089A (en) | 2018-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940658A (en) | Chinese medicinal composition for treating toothache and preparation method thereof | |
| CN101502588B (en) | Composition for beauty treatment and removing blain and method for preparing the same | |
| CN102000175A (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN103007012B (en) | Traditional Chinese medicine composition for treating toothaches and preparation method thereof | |
| CN1977959A (en) | Chinese medicine compound preparation for comprehensively regulating body function and its preparing method | |
| CN101940733A (en) | Traditional Chinese medicinal composition for curing nephritis diseases and preparation method thereof | |
| CN113713039A (en) | Traditional Chinese medicine composition for treating membranous nephropathy and application thereof | |
| CN105497439A (en) | Medicine composition for treating gynecological postoperative low fever | |
| CN104922426A (en) | Pharmaceutical composition for treating post gynecologic operation low fever | |
| CN108721431B (en) | Traditional Chinese medicine composition for removing heavy metals and application thereof | |
| CN101269138B (en) | Traditional Chinese medicine for treating hemorrhoid | |
| CN102343019B (en) | Chinese medicinal composition for treating amenorrhea and preparation method of preparation thereof | |
| CN108079089B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN105055841A (en) | Medicine for treating chronic pharyngitis and preparing method thereof | |
| CN102114189A (en) | Chinese medicinal blood glucose reducing tablet for treating diabetes comprising superfine powder | |
| CN103463449A (en) | Traditional Chinese medicine composite used for treating haemorrhoids and preparation method and application thereof | |
| CN113616758A (en) | Traditional Chinese medicine suitable technology for treating functional constipation of children by external application of medicine | |
| CN100441166C (en) | Combination of medication of containing medicinal rhubarb and activated carbon or carbo medicinalis | |
| WO2022057157A1 (en) | Traditional chinese medicine composition for treating precocious puberty in children, and preparation method therefor and use thereof | |
| CN103690869B (en) | Chinese medicine for the treatment of irritable bowel syndrome and preparation method thereof | |
| CN102327526B (en) | Traditional Chinese medicine composition for lowering blood sugar | |
| CN101269130B (en) | Chinese medicinal composition for treating hemorrhoid | |
| CN104399036A (en) | Medicine composition for treating chronic diarrhea and application of medicine composition | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN104147229B (en) | A kind of compound Chinese medicinal preparation for the treatment of female climacteric syndrome kidney yin and yang deficiency type |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |